Young child with Doctor

Here in our Media Centre you will find corporate press releases and other useful information for business and financial media

Latest press releases

Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency
22 January 2015
PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses
14 January 2015
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
12 January 2015
LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations   
19 December 2014
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
18 December 2014
AstraZeneca and Amgen to present detailed results from Phase III AMAGINE-1™ study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis
11 December 2014
MOVENTIG® approved in the European Union for opioid-induced constipation
9 December 2014
Jury verdict favours AstraZeneca in Nexium antitrust litigation
5 December 2014
New Drug Application for IRESSA accepted by US Food and Drug Administration
2 December 2014
AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer’s disease
1 December 2014
MedImmune completes acquisition of Definiens
26 November 2014
Amgen and AstraZeneca announce positive results from third and final pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis
25 November 2014

Fast facts

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas.

Sign up to email alerts

Your email address will only be used to provide you with services from AstraZeneca that you requested. You can opt out for email subscriptions any time. Your personal information will not be provided to any third party without your permission.